Hemolytic uremic syndrome without hemolytic anemia: a case report

Hemolytic uremic syndrome (HUS) typically involves microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Most cases are linked to E. coli O157:H7 and its verotoxin. Prior research has shown that this toxin causes endothelial damage, leading to the classic triad of symptoms. However, a subset of patients may exhibit atypical features. This gap motivated the investigation of a case where HUS-like renal findings occurred without hemolytic anemia. No prior work had resolved how such a scenario could arise. The absence of hemolysis in some HUS cases raises questions about protective mechanisms. Understanding these variations could improve diagnostic accuracy and treatment strategies. This uncertainty drove the need to explore the role of red blood cell antigens in toxin adsorption.

The aim of this case report is to describe a patient with HUS-like renal findings but no hemolytic anemia. The specific problem is the absence of the typical triad of symptoms in a patient with confirmed E. coli O157:H7 infection. The motivation stems from the need to understand atypical presentations of HUS. This case highlights the importance of considering alternative explanations for renal failure in such contexts. The study seeks to identify potential protective factors that may prevent hemolysis. It also aims to clarify the role of red blood cell antigens in toxin interaction. The absence of hemolytic markers in this patient challenges conventional diagnostic criteria. This case provides insight into the variability of HUS manifestations.

The study involved a detailed clinical and laboratory evaluation of a single patient. The patient's history included a prolonged E. coli O157:H7 infection followed by acute renal failure. Renal biopsy was performed to assess histological changes. The biopsy revealed mesangiolysis and capillary wall thickening, typical of HUS. Blood tests were conducted to measure LDH and haptoglobin levels. These markers remained within normal ranges throughout the clinical course. The patient's red blood cells were tested for P1 antigen expression. The presence of this antigen was linked to toxin adsorption and potential organ protection. These methods allowed for a comprehensive assessment of the patient's condition.

The patient's renal biopsy showed classic HUS features, including mesangiolysis and capillary wall thickening. However, no signs of hemolytic anemia were observed. LDH and haptoglobin levels remained normal throughout the illness. The patient's red blood cells expressed the P1 antigen. This antigen is known to adsorb verotoxin, potentially limiting organ damage. The absence of hemolysis suggests a protective role for the P1 antigen. The patient's kidneys showed less severe damage compared to typical HUS cases. These findings support the hypothesis that P1 antigen expression may prevent microangiopathic hemolytic anemia.

The authors propose that P1 antigen expression may protect against hemolytic anemia in HUS. This case suggests that the presence of P1 antigen can adsorb verotoxin, preventing damage to red blood cells. The absence of hemolysis in this patient supports this hypothesis. The renal findings were typical of HUS despite the lack of hemolytic anemia. This case highlights the variability of HUS presentations. The study does not claim that P1 antigen is essential for protection in all cases. It suggests that further research is needed to confirm this mechanism in other patients. The findings may inform future diagnostic approaches for atypical HUS cases.